Abstract
Despite fundamental advances in the field of oncology, the prognosis of leptomeningeal metastasis (LMD) remains poor, with the average overall survival typically measured in weeks to a few months. Malignant melanoma (MM) is one of the solid malignancies with the highest tendency to metastasize to this space: approximately 10–15% of patients with advanced MM develop LMD. In addition to diagnostic challenges, the incidence of LMD appears to be rising; currently available treatment options appear to have very little impact on survival. This review provides a short overview of the epidemiology, diagnosis, and current treatment approaches for MM patients with LMD. Finally, currently ongoing clinical trials are briefly reviewed, for which promising and trendsetting results have already been presented.
Translated title of the contribution | Current therapeutic approaches in malignant melanoma patients with leptomeningeal disease |
---|---|
Original language | German |
Pages (from-to) | 96-102 |
Number of pages | 7 |
Journal | Best Practice Onkologie |
Volume | 17 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2022 |
Keywords
- CNS microenvironment
- Intrathecal therapy
- Leptomeningeal carcinomatosis
- Leptomeningeal disease
- Melanoma
ASJC Scopus subject areas
- Oncology